Onglyza accepted for use in NHS Scotland

The Scottish Medicines Consortium (SMC) has accepted saxagliptin (Onglyza) for restricted use within NHS Scotland in adult patients with type 2 diabetes mellitus as add-on therapy with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control. It is restricted to use only when the addition of sulfonylureas is not appropriate and is an alternative to other agents such as thiazolidinediones.

The SMC advises that the efficacy of saxagliptin, as assessed by measurement of HbA1c, is comparable to that of another dipeptidyl peptidase 4 inhibitor and that the drug appears to have minimal effect on body weight.

This SMC assessment related only to the use of saxagliptin in combination with metformin; therefore, the SMC cannot recommend the use of saxagliptin in combination with sulfonylureas or thiazolidinediones.

New guidance on the treatment of diabetes in Scotland, recently issued by the Scottish Intercollegiate Guidelines Network (SIGN), includes recommendations on the use of dipeptidyl peptidase 4 inhibitors.

View Onglyza drug record

Further information: SMC

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases